A Guide Across Mounjaro Dosage Chart
Finding the right dose can feel like navigating a maze, particularly when treatment is built around gradual increases rather than a single prescribed amount. Mounjaro, whose active ingredient is tirzepatide, follows a structured once-weekly schedule designed to let the body adjust while blood glucose control improves.
This guide sets out what the prescribing information actually says: the adult and pediatric dosing steps, how long to stay at each one, what happens after a missed dose, and why the escalation exists in the first place.
Medical disclaimer. This article is educational and does not replace individualized medical advice, diagnosis or treatment. Mounjaro is a prescription medicine, and dosing decisions belong with the prescribing healthcare professional.
What Is Mounjaro?
Mounjaro is a prescription injectable containing tirzepatide, which acts on two hormone receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). It is indicated as an adjunct to diet and exercise to improve glycemic control in adults and in pediatric patients aged 10 years and older with type 2 diabetes.
It is administered subcutaneously once weekly, with adult strengths running from 2.5 mg to 15 mg. Those strengths are steps in a schedule rather than alternatives to choose between, which is the single most important thing to understand before reading any dosage chart.
Readers comparing it with other once-weekly options may find our Mounjaro vs Ozempic comparison useful. Tirzepatide is also marketed as Zepbound for weight-management indications. Mounjaro itself is prescribed for its diabetes indication, and while patients often lose weight during treatment, weight reduction is not what the Mounjaro label covers.
The Mounjaro Dosage Chart for Adults
The prescribing information sets a starting dose of 2.5 mg once weekly, an increase to 5 mg after four weeks, and further increases in 2.5 mg steps with at least four weeks at each dose before moving up.
| Step | Dose | Minimum time before increasing | Purpose |
|---|---|---|---|
| Initiation | 2.5 mg once weekly | 4 weeks | Treatment initiation only, not intended for glycemic control |
| Step 2 | 5 mg once weekly | 4 weeks | First therapeutic dose |
| Step 3 | 7.5 mg once weekly | 4 weeks | If additional glycemic control is needed |
| Step 4 | 10 mg once weekly | 4 weeks | If additional glycemic control is needed |
| Step 5 | 12.5 mg once weekly | 4 weeks | If additional glycemic control is needed |
| Maximum | 15 mg once weekly | Maintenance | Maximum recommended adult dosage |
Two details are easy to miss. The 2.5 mg dose is explicitly for initiation and is not expected to control blood glucose on its own, so a patient who sees little change in the first month is not failing treatment. And not everyone needs to reach 15 mg: many people settle at a lower maintenance dose that meets their glycemic targets.
Pediatric Dosing
For pediatric patients aged 10 years and older, the escalation follows the same shape but stops earlier.
| Parameter | Adults | Pediatric patients 10 years and older |
|---|---|---|
| Starting dose | 2.5 mg once weekly | 2.5 mg once weekly |
| First increase | To 5 mg after 4 weeks | To 5 mg after at least 4 weeks |
| Increment | 2.5 mg after at least 4 weeks | 2.5 mg after at least 4 weeks |
| Maximum dosage | 15 mg once weekly | 10 mg once weekly |
Pediatric treatment should be managed by a clinician who can weigh the child’s age, health status, response and other medications.
Why the Escalation Exists
Tirzepatide commonly causes gastrointestinal effects, and those effects cluster at treatment start and after each dose increase. The four-week interval is what gives the gut time to adapt, which is why the label frames escalation as a way to reduce the risk of gastrointestinal adverse reactions rather than as a formality.
Moving faster than the schedule does not produce faster results; it produces more nausea. A patient who feels ready to jump ahead should raise it with their prescriber rather than acting on it, and our guide on how long Mounjaro takes to work covers what the realistic timeline looks like.
How and When to Inject
Mounjaro is given once weekly at any time of day, with or without meals. It is injected subcutaneously into the abdomen or thigh; the back of the upper arm can be used when another person administers the injection. Injection sites are rotated with each dose.
The day of the week can be changed if needed, provided the interval between doses is at least 72 hours.
What to Do About a Missed Dose
If a dose is missed, it can be taken as soon as possible within four days, meaning 96 hours, of the scheduled day. If more than four days have passed, the missed dose is skipped and the next one is taken on the regular day. In both cases the usual weekly schedule resumes afterwards.
Doses should never be doubled up to compensate for a missed injection.
Side Effects to Expect
Gastrointestinal reactions are the most frequently reported, particularly early in treatment or after an increase:
- Nausea;
- Diarrhea;
- Reduced appetite;
- Vomiting;
- Constipation;
- Indigestion;
- Abdominal pain or discomfort.
Persistent or severe symptoms warrant a call to the prescriber, who may hold the dose at its current step rather than increasing it. Combining Mounjaro with insulin or with medicines that stimulate insulin secretion raises the risk of hypoglycemia, which may require the other medication to be adjusted.
Contraindications and Precautions
Mounjaro is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and in anyone with known serious hypersensitivity to tirzepatide or to any excipient. The thyroid warning derives from rodent studies in which tirzepatide caused thyroid C-cell tumors; whether that applies to humans is not established.
Additional caution applies around pancreatitis, severe gastrointestinal disease, diabetic retinopathy and renal impairment linked to dehydration from gastrointestinal effects. A full medication list, including over-the-counter products and supplements, belongs in that conversation.
Why the Right Dose Is Personal
A dosage chart describes a framework, not a target. Two people with the same diagnosis can end up on different doses because glycemic response, tolerability, other medications, age and medical history all feed into the decision.
Patients switching from another GLP-1 medicine should not map doses across by themselves either; our Ozempic to Mounjaro conversion guide explains why the units do not translate directly. That is also why doses should not be increased, reduced or stopped without the prescriber, and why follow-up matters: a dose that suits a patient this year may need revisiting next year.
FAQs
What is the starting dose of Mounjaro?
2.5 mg once weekly. The label states explicitly that this dose is for treatment initiation and is not intended for glycemic control, which is why it is followed by an increase to 5 mg after four weeks.
How quickly can the dose be increased?
No sooner than every four weeks. After the move to 5 mg, further increases are made in 2.5 mg steps with at least four weeks spent at the current dose before each one.
What is the maximum dose of Mounjaro?
15 mg once weekly for adults. For pediatric patients aged 10 years and older, the maximum recommended dosage is 10 mg once weekly.
Does everyone need to reach the maximum dose?
No. Many patients achieve their glycemic targets at a lower maintenance dose, and the prescriber may keep a patient at a given step based on response and tolerability rather than escalating further.
What happens if a weekly dose is missed?
It can be taken within four days of the scheduled day. Beyond that window the dose is skipped and the next injection is taken as normal. Two doses should not be taken close together to make up for one that was missed.
Is Mounjaro approved for weight loss?
Not under that brand name. Mounjaro is indicated for glycemic control in type 2 diabetes; tirzepatide is marketed as Zepbound for weight-management indications. Patients often lose weight on Mounjaro, but the prescription should match the indication.
Where can Mounjaro be bought with a prescription?
Patients with a valid prescription can order Mounjaro from Insulin.store, which ships from Canada across the full range of pen strengths, including the 10 mg KwikPen.
References
Eli Lilly and Company. (2026). MOUNJARO (tirzepatide) injection, for subcutaneous use: highlights of prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
Rosenstock, J., Wysham, C., Frias, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. https://doi.org/10.1016/S0140-6736(21)01324-6
Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. The New England Journal of Medicine, 385(6), 503-515. https://doi.org/10.1056/NEJMoa2107519
Hannon, T. S., Chao, L. C., Barrientos-Perez, M., et al. (2025). Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 406(10511), 1484-1496. https://doi.org/10.1016/S0140-6736(25)01774-X